Visus Therapeutics is a clinical-stage biotechnology company that develops gene therapies for ocular diseases. The company's lead product candidate, BRIMOCHOL, is a combination of two drugs that are designed to treat presbyopia, a condition that affects the ability to focus on nearby objects. Visus Therapeutics was founded in 2014 and is headquartered in Waltham, Massachusetts.